You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Harvard Business School
Moodys
Baxter
Colorcon

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

TAMOXIFEN CITRATE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Tamoxifen Citrate, and when can generic versions of Tamoxifen Citrate launch?

Tamoxifen Citrate is a drug marketed by Actavis Labs Fl Inc, Aegis Pharms, Apotex, Eugia Pharma, Ivax Sub Teva Pharms, Mayne Pharma, Mylan, Pharmachemie, Roxane, Teva, and Zydus Pharms. and is included in twelve NDAs.

The generic ingredient in TAMOXIFEN CITRATE is tamoxifen citrate. There are sixteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the tamoxifen citrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tamoxifen Citrate

A generic version of TAMOXIFEN CITRATE was approved as tamoxifen citrate by ACTAVIS LABS FL INC on February 20th, 2003.

  Get Started for $10

Drug patent expirations by year for TAMOXIFEN CITRATE
Drug Prices for TAMOXIFEN CITRATE

See drug prices for TAMOXIFEN CITRATE

Drug Sales Revenue Trends for TAMOXIFEN CITRATE

See drug sales revenues for TAMOXIFEN CITRATE

Recent Clinical Trials for TAMOXIFEN CITRATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Baylor College of MedicineEarly Phase 1
TYK Medicines, IncPhase 1
NanoString Technologies, Inc.Phase 2

See all TAMOXIFEN CITRATE clinical trials

Pharmacology for TAMOXIFEN CITRATE
Paragraph IV (Patent) Challenges for TAMOXIFEN CITRATE
Tradename Dosage Ingredient NDA Submissiondate
NOLVADEX TABLET;ORAL tamoxifen citrate 017970

US Patents and Regulatory Information for TAMOXIFEN CITRATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Labs Fl Inc TAMOXIFEN CITRATE tamoxifen citrate TABLET;ORAL 070929-001 Feb 20, 2003 AB RX No No   Get Started for $10   Get Started for $10   Get Started for $10
Roxane TAMOXIFEN CITRATE tamoxifen citrate TABLET;ORAL 076027-001 Feb 20, 2003 DISCN No No   Get Started for $10   Get Started for $10   Get Started for $10
Apotex TAMOXIFEN CITRATE tamoxifen citrate TABLET;ORAL 090878-001 Sep 23, 2011 AB RX No No   Get Started for $10   Get Started for $10   Get Started for $10
Actavis Labs Fl Inc TAMOXIFEN CITRATE tamoxifen citrate TABLET;ORAL 076179-002 Feb 20, 2003 DISCN No No   Get Started for $10   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Harvard Business School
Baxter
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.